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Identification of the metabolic 
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multidrug resistant phenotype 
in cancer and their intercellular 
transfer mediated by extracellular 
vesicles
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Michael Henry4, Milica Pesic6, Diana Cabrera5, Sebastiaan van Liempd5, Raquel T. Lima1,2,7, 
Robert O’Connor4, Juan M. Falcon-Perez5,8 & M. Helena Vasconcelos1,2,9
Multidrug resistance (MDR) is a serious obstacle to efficient cancer treatment. Overexpression of 
P-glycoprotein (P-gp) plays a significant role in MDR. Recent studies proved that targeting cellular 
metabolism could sensitize MDR cells. In addition, metabolic alterations could affect the extracellular 
vesicles (EVs) cargo and release. This study aimed to: i) identify metabolic alterations in P-gp 
overexpressing cells that could be involved in the development of MDR and, ii) identify a potential 
role for the EVs in the acquisition of the MDR. Two different pairs of MDR and their drug-sensitive 
counterpart cancer cell lines were used. Our results showed that MDR (P-gp overexpressing) cells have 
a different metabolic profile from their drug-sensitive counterparts, demonstrating decreases in the 
pentose phosphate pathway and oxidative phosphorylation rate; increases in glutathione metabolism 
and glycolysis; and alterations in the methionine/S-adenosylmethionine pathway. Remarkably, EVs 
from MDR cells were capable of stimulating a metabolic switch in the drug-sensitive cancer cells, 
towards a MDR phenotype. In conclusion, obtained results contribute to the growing knowledge about 
metabolic alterations in MDR cells and the role of EVs in the intercellular transfer of MDR. The specific 
metabolic alterations identified in this study may be further developed as targets for overcoming MDR.
The development of multidrug resistance (MDR) in cancer is a serious impediment to treatment success. MDR 
is defined as a phenotype of the cells resistant to multiple structurally and functionally different drugs. Such 
resistance is multifactorial and may be due to various mechanisms1,2. There are several important mechanisms 
involved in MDR whose identification has generated valuable information on how to circumvent MDR and 
improve chemotherapy treatment.
One of the most important known mechanism is the overexpression of ATP-binding cassette (ABC) transport-
ers, commonly known as drug efflux pumps, such as P-glycoprotein (P-gp)2, which is frequently overexpressed 
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in cancer3. P-gp transports drug-substrates across the cell membrane, thus decreasing their intracellular concen-
trations to sub-lethal4.
Several studies pointed to a relation between MDR and alterations in cellular metabolism: (i) upregulation of 
hypoxia-induced factor 1 (HIF-1) was shown to be associated with chemoresistance5; (ii) leukemia models with 
higher glycolytic rates were resistant to glucocorticoids6; (iii) modulation of cellular metabolic pathways was 
demonstrated to contribute to acquired resistance in multiple myeloma cells7; (iv) glycolytic pyruvate was capa-
ble of regulating P-gp expression in multicellular tumor spheroids8; and (v) hypoxia was shown to induceMDR 
and glycolysis in an orthotopic MDR tumor model in nude mice9. Ultimatelly, these studies may contribute to 
understanding how MDR could be circumvented by application of specific metabolic modulators and inhibitors. 
Therefore, it is important to identify metabolic alterations in MDR cancer cells, which could lead to the identifi-
cation of new metabolic molecular targets to circumvent MDR in cancer.
The formation of Extracellular vesicles (EVs) and their release have been implicated in pathological pro-
cesses such as cancer10–12 and shown to be relevant for the intercellular transfer of a drug-resistant phenotype12–14. 
Indeed, drug-sensitive cancer cells can become drug-resistant following intracellular incorporation of EVs shed 
by drug-resistant cancer cells13–16. We have previously shown that the EVs population shed by MDR cells is differ-
ent from the one shed by drug-sensitive counterpart cells, thus suggesting that MDR cells produce more microve-
sicles and less exosomes than their drug-sensitive counterpart cells17. In addition, several studies have stated 
that metabolic alterations in cancer cells could induce alterations in the EVs’ cargo and its release18–20. So far, it is 
unclear if these metabolic alterations are caused by or could be responsible for the MDR phenotype.
Here we provide evidence that MDR cancer cell lines (overexpressing P-gp) acquired a different metabolic 
profile from their drug-sensitive counterpart cells and that the EVs released by MDR cells caused a metabolic 
switch towards the MDR phenotype in the recipient cells.
Results
Protein profiling and bioinformatics analysis of MDR and drug-sensitive counterpart cell lines 
identified differentially expressed proteins (DEPs). For protein profiling, each of the four biolog-
ical replicates of each condition was run by LC–MS. The data was transferred to Progenesis QI for proteom-
ics to compare drug-sensitive cancer cells (K562 and NCI-H460) with their MDR counterparts (K562Dox and 
NCI-H460/R). Individual comparisons were carried out for each pair of cell lines: K562 versus K562Dox and 
NCI-H460 versus NCI-H460/R. Following Progenesis LC–MS analysis, peptide features with ANOVA < 0.05 and 
1+ , 2+ and 3+ charge states were subjected to MASCOT database searching. The MASCOT mgf files were then 
resubmitted to the Progenesis software to yield a list of identified proteins. These lists were further interrogated to 
exclude proteins with less than 2 peptides matched, a fold change < 1.5 and not statistically significant.
A total of 91 significant (p < 0.05) differentially expressed proteins (DEPs) were identified when comparing 
the K562 vs. K562Dox cells and 67 significant DEPs (p < 0.05) were identified when comparing the NCI-H460 vs. 
NCI-H460/R cells. A full list of the DEPs identified for each cell line is available in the Supplementary Information 
(Tables S1 and S2).
Gene Ontology (GO) bioinformatics analysis indicated that the greatest difference between 
MDR cells and their drug-sensitive counterparts occurred in metabolic processes. Using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) network analysis tool, the molecular 
functions/localizations of the DEPs data sets were analyzed according to GO functional annotations and catego-
ries. GO analysis of cellular components, molecular functions and biological processes were performed on the 
91 DEPs (K562 vs. K562Dox) and 67 DEPs (NCI-H460 vs. NCI-H460/R) identified with the Progenesis software. 
Pie diagrams represent the GO analysis of the identified DEPs (Fig. 1). The GO analysis revealed that most of the 
DEPs (for both cancer cell models) have cytoplasmic origin (42% in K562 vs. K562Dox and 44% in NCI-H460 vs. 
NCI-H460/R), cytoskeleton origin (17% for both models) and membrane localization (6% in K562 vs. K562Dox 
and 5% in NCI-H460 vs. NCI-H460/R) (Fig. 1A). The functional classification of these proteins from both cancer 
cell models implied that they are mostly involved in catalytic activities, structure molecule activities and protein 
binding activities (Fig. 1B). Noteworthy, analysis of the biological processes indicated that the greatest difference 
between the MDR cells and their drug-sensitive counterparts occurred in metabolic processes (50% in K562 vs. 
K562Dox and 63% in NCI-H460 vs. NCI-H460/R) (Fig. 1C). The remaining different biological processes were 
associated with transport, development processes and cell organization and biogenesis.
KEGG pathway enrichment analysis indicated that the most significant active pathways 
enriched in the MDR cells were involved in metabolic processes. Following the identification of 
the DEPs, the most significant active pathways were analyzed using KEGG pathway enrichment analysis. Results 
indicated that the most significantly active pathways enriched in the MDR cells were those involved in metabolic 
processes. The glutathione metabolism (GSH), pentose phosphate pathway (PPP) and glycolysis were found to 
be the most enriched pathways identified in both cancer cell models (Table 1). In the chronic myeloid leukemia 
model (K562Dox) the following 4 DEPs were found to be involved in the GSH metabolism pathway (G6PD, 
PRDX2, IDH1 and 6PGD), 3 DEPs in the PPP pathway (G6PD, ALDOC and 6PGD) and 2 DEPs in the glycolysis 
pathway (ALDOC and PKM2). In the non-small cell lung cancer model the following 5 DEPs were found to be 
involved in the GSH metabolism pathway (G6PD, PRDX2, IDH1, MGST1 and 6PGD), 4 DEPs in the PPP path-
way (G6PD, TALDO1, TKT and 6PGD) and 1 DEP involved in the glycolysis pathway (ALDH3A1) (Table 1).
Other DEPs involved in MDR and metabolic processes were identified by bioinformatics analysis. 
In addition to the DEPs referred above (Table 1) other DEPs also involved in metabolic process and MDR were 
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analyzed in terms of normalized abundance between MDR and drug-sensitive counterpart cells (for both cancer 
cell models) (Table 2).
The DEP with the highest fold change was P-gp, which was upregulated in both MDR cells with a fold change 
of 18.8 for K562Dox vs. K562 and 64.5 for NCI-H460/R vs. NCI-H460. In terms of metabolic processes, most of 
the DEPs involved in the PPP pathway were downregulated in the two MDR models (ALDOC, G6PD, 6PGD and 
TKT) and only TALDO1 was upregulated in the NCI-H460/R cells (Table 2). Regarding GSH metabolism, the 
enzymes responsible for the NADP+ reduction to NADPH (G6PD, 6PGD and IDH1) were downregulated in the 
MDR cells but MGST1 was upregulated in NCI-H460/R cells. Regarding glycolysis, ALDOC was downregulated 
in MDR cells but the enzyme responsible for the pyruvate production (PKM2) was upregulated. Additionally, 
DEPs involved in the TCA cycle were also identified (ACLY and ACO2). ACLY was upregulated whereas ACO2 
was downregulated in the MDR cancer cell models (Table 2).
Interestingly HYOU1 and NDRG1 (both involved in cellular response to hypoxia) and MTHFD1 (an enzyme 
involved in the methionine pathway) were upregulated in the MDR cells (Table 2).
Results obtained by quantitative label-free proteomic approach were validated by Western 
blot. The expression of P-gp, G6PD, 6PGD and IDH1 were further validated by Western blot. We focused the 
validation on DEPs involved in MDR, glutathione metabolism and pentose phosphate pathway. Consistent with 
the results obtained with the proteomic analysis, P-gp was found upregulated while G6PD, 6PGD and IDH1 were 
downregulated in the MDR cells (K562Dox and NCI-H460/R) when compared with their drug-sensitive coun-
terpart cells (K562 and NCI-H460) (Fig. 2).
MDR cells presented higher levels of reduced glutathione (GSH) and lower levels of reactive 
oxygen species (ROS). Since most of the proteins that had been identified as DEPs in MDR cells were 
related to metabolic processes such as GSH metabolism and PPP, the GSH (one of the main detoxification agents 
in the cell) and ROS levels were analyzed in both tumor models.
MDR cells (K562Dox and NCI-H460/R) presented significantly higher levels of GSH when compared to their 
drug-sensitive counterpart cells (K562 and NCI-H460) (Fig. 3A,B). In agreement with this higher capacity pro-
vided by the higher levels of GSH to respond to oxidative stress, MDR cells presented lower levels of ROS when 
compared to their drug-sensitive counterpart cells (Fig. 3C,D).
Changes in methionine/S-adenosylmethionine pathway were identified in the MDR cancer 
cells. As we found GSH significantly increased in MDR cells, we were also interested in studying the met-
abolic pathways involved in the biosynthesis of GSH. The main cellular pathway that generates precursor for 
the synthesis of GSH corresponds to the methionine/S-adenosylmethionine (SAMe) pathway. By UPLC-MS 
metabolomics21 we have quantified metabolites belonging to this pathway in the MDR and their drug-sensitive 
counterpart cells (Table 3 and Table S3). Methionine was upregulated in both MDR cancer cells. On the contrary, 
S-adenosylhomocysteine (SAH) and spermidine were downregulated in both MDR cancer cell lines (K562Dox 
and NCI-H460/R) (Table 3). In addition, no alterations in S-adenosylmethionine (SAMe) were found in both 
cancer cell models (Table 3). Some other metabolites were found altered (such as (MTA, dcSAMe, betaine, choline 
and serine) but in different manners between the two cancer models.
Furthermore, the methylation index (SAMe/SAH), which represents the methylation capacity of the cells, was 
higher in MDR cells. In the chronic myeloid leukemia model, K562 cells had a methylation index of 6.97, whereas 
the methylation index for K562Dox cells was 12.05. In the non-small cell lung cancer model, NCI-H460 cells had 
a methylation index of 2.43 whereas the methylation index for NCI-H460/R cells was 9.79.
MDR cells (NCI-H460/R) showed an increase in the non-glycolytic acidification, glycolysis, gly-
colytic capacity and glycolytic reserve. In order to gain new insights into the metabolic phenotype of 
MDR cells, the extracellular acidification rate (ECAR), which reflects the rate of glycolysis, and the oxygen con-
sumption rate (OCR), which reflects the rate of oxidative phosphorylation (OXPHOS), were measured in both 
MDR and sensitive cancer cells. Measurements were performed in both basal cellular state and after treatments 
with compounds capable of modulating glycolysis and OXPHOS.
To analyze the glycolytic function, a glycolysis stress test was performed. The ECAR was measured in cells 
treated sequentially with: their glucose-free assay media as a control (Fig. 4A, blue line A); then with glucose to 
allow the cells to enter into glycolysis (Fig. 4A, blue line B); next with olygomycin (an ATP coupler) in order to 
inhibit ATP synthesis by blocking the proton channel and shifting the energy production to glycolysis (Fig. 4A, 
blue line C); and finally with 2-deoxyglucose (2-DG) which is a glucose analog that inhibits glycolysis through 
competitive binding to glucose hexokinase (Fig. 4A, blue line D). The resulting data allowed calculating the fol-
lowing parameters: Non-glycolytic acidification (= last rate measurement prior to glucose injection); Glycolysis 
(= maximum rate measurement before oligomycin injection – last rate measurement before glucose injection); 
Glycolytic capacity (= maximum rate measurement after oligomycin injection – last rate measurement before 
glucose injection); Glycolytic reserve (= glycolytic capacity – glycolysis).
In terms of glycolytic function, the MDR cells (NCI-H460/R) showed a statistically significant increase in the 
non-glycolytic acidification, glycolysis, glycolytic capacity and glycolytic reserve, when compared to their drug 
sensitive counterpart cells (NCI-H460) (Fig.4A).
To analyze the mitochondrial respiration, a mitochondrial stress test was performed. The OCR was measured 
during cells’ treatment with: corresponding assay media (Fig. 4B, blue line A); then with olygomycin (Fig. 4B, 
blue line B); next with FCCP (electron transporter chain accelerator) that is an uncoupling agent which dis-
rupts ATP synthesis leading to the collapse of the mitochondrial membrane potential and causing rapid con-
sumption of energy and oxygen without the generation of ATP (Fig. 4B, blue line C); and finally with rotenone 
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(complex I inhibitor) which shuts down mitochondrial respiration by preventing the transfer of electrons from 
complex I to coenzyme Q (Fig. 4B, blue line D). These modulators allowed to calculate the following parame-
ters: Non-mitochondrial respiration (= minimum rate measurement after rotenone injection); Basal respiration 
(= last rate measurement before first injection - non-mitochondrial respiration rate); Maximal respiration (= 
maximum rate measurement after FCCP injection – non-mitochondrial respiration); Proton leak (= minimum 
rate measurement after olygomycin injection – non-mitochondrial respiration); ATP production (= last rate 
measurement before olygomycin injection – minimum rate measurement after olygomycin injection); Spare 
capacity (= maximal respiration – basal respiration).
Regarding the mitochondrial respiration, the MDR cells showed a statistically significant decrease in the 
non-mitochondrial respiration, basal respiration, maximal respiration, proton leak, ATP production and spare 
capacity (Fig. 4B).
PPP inhibitor changed the metabolic phenotype of NCI-H460 cells towards the phenotype of 
their MDR counterparts (NCI-H460/R). As aforementioned, sensitive cells possess more rate limiting 
enzymes of the PPP than their corresponding MDR cells (Tables 1 and 2 and Fig. 2). In addition, they showed 
a decrease in glycolytic parameters (Fig. 4A) and an increase in mitochondrial respiration (Fig. 4B). In order to 
confirm that the PPP is involved in the MDR phenotype, NCI-H460 cells (drug-sensitive) were treated with a 
Figure 1. GO analysis of all the differentially expressed proteins (DEPs) identified with the Progenesis 
QI software in both pairs of counterpart drug-sensitive and MDR cancer cell lines: K562 versus K562Dox 
and NCI-H460 versus NCI-H460/R. (A) GO - Cellular component analysis of the identified proteins; (B) 
GO - Molecular functional analysis of the identified proteins; and (C) GO - Biological process analysis of the 
identified proteins.
Term Counta ANOVA (P) Genes Symbol
K562 vs. 
K562Dox
Glutathione metabolism 4 0.0086 G6PD, PRDX2, IDH1, 6PGD
Pentose phosphate pathway 3 0.0025 G6PD, ALDOC, 6PGD
Glycolysis 2 0.01 ALDOC, PKM2
NCI-H460 vs. 
NCI-H460/R
Glutathione metabolism 5 0.00064 G6PD, 6PGD. IDH1, MGST1, PRDX2
Pentose phosphate pathway 4 0.00099 G6PD, 6PGD, TKT, TALDO1
Glycolysis 1 nd ALDH3A1
Table 1.  Metabolic pathways found enriched with DEPs in MDR cells. Results were analyzed with DAVID 
software for KEGG pathway enrichment. aNumber of proteins involved in each pathway. nd – no data.
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sub-lethal concentration of dichloroacetate (DCA, a PPP inhibitor) and consequent alterations in glycolysis and 
OXPHOS were observed. After DCA treatment, the drug-sensitive cells acquired a metabolic phenotype similar 
to the one observed in the MDR cells, presenting an increase in glycolysis, glycolytic capacity and glycolytic 
reserve, and a decrease in their basal respiration, maximal respiration and ATP production by OXPHOS (Fig. 5). 
The MDR cells (NCI-H460/R) treated with DCA showed no changes in glycolytic function and mitochondrial 
respiration (data not shown).
P-gp inhibitor changed the metabolic phenotype of MDR cells (NCI-H460/R) towards the phe-
notype of their corresponding sensitive cells (NCI-H460). In order to confirm the possible influence 
of P-gp in the observed metabolic alterations of the MDR cells, the NCI-H460/R were treated with a sub-lethal 
concentration of a well-known P-gp inhibitor, verapamil, and the levels of glycolysis and OXPHOS were analyzed. 
UniProt 
accession no. Protein description Gene Symbol Peptides Mascot Score
ANOVA 
(P)
Fold 
Changea
K562 vs. K562Dox
Increased in MDR cells
P08183 P-glycoprotein MDR1 6 404.08 1.24e-009 18.80
Q9Y4L1 Hypoxia up-regulated protein 1 HYOU1 4 282.01 3.19e-005 2.05
Q92597 Protein NDRG1 NDRG1 2 118.12 4.32e-006 1.84
P53396 ATP-citrate synthase ACLY 5 289.70 7.19e-006 1.84
P14618 Pyruvate kinase PKM2 10 706,77 4,25E-03 1.52
P11586 C-1-tetrahydrofolate synthase MTHFD1 2 97,89 9,83E-04 1.51
Decreased in MDR cells
P09972 Fructose-bisphosphate aldolase C ALDOC 7 550.98 0.01 0.66
P52209 6-phosphogluconate dehydrogenase 6PGD 2 111,38 2,84E-03 0.65
O75874 Isocitrate dehydrogenase IDH1 3 218,56 2,63E-05 0.65
P32119 Peroxiredoxin-2 PRDX2 5 372.45 1.35e-003 0.60
P11413 Glucose-6-phosphate 1-dehydrogenase G6PD 4 250.70 7.79e-007 0.39
NCI-H460 vs. 
NCI-H460/R
Increased in MDR cells
P08183 Multidrug resistance protein 1 MDR1 2 175.04 9.14E-06 64.52
P10620 Microsomal glutathione S-transferase 1 MGST1 2 105,19 1.33e-004 1.80
P37837 Transaldolase TALDO1 2 116.98 4.64e-004 1.53
Decreased in MDR cells
O75874 Isocitrate dehydrogenase IDH1 4 327.28 7.79E-05 0.66
Q99798 Aconitate hydratase, mitochondrial ACO2 2 132,35 2.38e-003 0.63
P29401 Transketolase TKT 8 489.12 7.25e-005 0.60
P52209 6-phosphogluconate dehydrogenase 6PGD 7 570.89 3.89E-06 0.54
P32119 Peroxiredoxin-2 PRDX2 2 133.35 0.02 0.52
P11413 Glucose-6-phosphate 1-dehydrogenase G6PD 13 1012.11 1.22E-06 0.41
P30838 Aldehyde dehydrogenase ALDH3A1 6 352,67 1.74e-005 0.40
Table 2.  DEPs involved in MDR and metabolic processes. aMDR cells/Drug-sensitive cells.
Figure 2. Validation by Western blot analysis of some DEPs initially identified by quantitative proteomics. 
Representative blots were chosen from three independent experiments. Actin was used as a loading control.
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After treatment with verapamil, the MDR cells acquired a metabolic phenotype more similar to the one observed 
in sensitive cells, presenting a decrease in glycolysis, glycolytic capacity, glycolytic reserve and non-glycolytic 
acidification, and an increase in their basal respiration (Fig. 6).
PPP inhibitor increased resistance of sensitive cells (NCI-H460) to doxorubicin. To evaluate the 
possible contribution of PPP to the MDR phenotype, the NCI-H460 cells were pre-treated with a sub-lethal 
concentration of PPP inhibitor - DCA and then subjected to doxorubicin treatment (37.5 nM). The relative cell 
number was assessed and the ratio between sensitive cells treated with DCA and without DCA was calculated. 
The sensitive cells pre-treated with DCA were more resistant to doxorubicin compared to sensitive cells without 
DCA pre-treatment (Fig. 7A). The increase in doxorubicin resistance was also observed when cells were treated 
with higher concentrations of doxorubicin (75 nM and 150 nM) (data not shown).
P-gp inhibitor sensitized MDR cells (NCI-H460/R) to doxorubicin. To confirm the P-gp involvement 
in the MDR phenotype, the NCI-H460/R cells were pre-treated with a sub-lethal concentration of P-gp inhibitor - 
verapamil and then subjected to doxorubicin treatment (37.5 nM). The relative cell number was assessed and the 
ratio between MDR cells treated with verapamil and without verapamil was calculated. The MDR cells pre-treated 
with verapamil were more sensitive to doxorubicin compared to MDR cells without verapamil pre-treatment 
(Fig. 7B). The sensitization of MDR cells to doxorubicin was also observed with other concentrations of doxoru-
bicin in a dose dependent manner (75 nM and 150 nM, data not shown).
EVs from MDR cells were able to transfer their metabolic phenotype to the sensitive 
cells. Next, we wanted to verify if MDR phenotype could be transferred to the drug-sensitive cells via EVs 
shed by the MDR cells. Therefore, drug-sensitive cells (NCI-H460) were treated with EVs isolated from the coun-
terpart pairs of non-small cell lung cancer cells (NCI-H460 and NCI-H460/R) and chronic myeloid leukemia cells 
(K562 and K562Dox) (Fig. S1). After 15 h incubation, the drug-sensitive cells treated with the EVs shed by MDR 
cells (NCI-H460/R - Fig. 8A and K562Dox - Fig. 8B) acquired a metabolic phenotype more similar to the MDR 
cellular phenotype, i.e., an increase in glycolysis and in glycolytic capacity.
Discussion
Multidrug resistance (MDR) is a major problem in cancer treatment, responsible for chemotherapy failure4. MDR 
cancer cells usually have multiple mechanisms of resistance14. One of the most frequent MDR mechanisms is 
Figure 3. Comparison of GSH and ROS levels between drug-sensitive and MDR cancer cell lines. (A) 
GSH levels in K562 and K562Dox cells. (B) GSH levels in NCI-H460 and NCI-H460/R cells. GSH levels are 
represented as Relative Luminescence Units (RLU). (C) ROS levels in K562 and K562Dox cells. (D) ROS levels 
in H460 and NCI-H460/R cells. The ROS levels are represented as mean fluorescence. Staurosporine was used as 
a positive control. Results are the mean ± SEM of 3 independent experiments. *p ≤ 0.05 and **p ≤ 0.01.
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the overexpression of ABC transporters, such as P-gp2. Recent findings pointed that altered metabolic path-
ways help cancer cells to proliferate, adapt their metabolism to nutrient limited conditions, and importantly 
develop drug resistant phenotypes22. Therefore, targeting cellular metabolism could chemosensitize MDR 
cells9,23,24. Understanding the metabolic adaptations of MDR cancer cells is important for the identification of 
new approaches to counteract this phenotype.
In the present study, we have identified a complex network of metabolic alterations associated with the MDR 
phenotype that could lead to the identification of more efficient therapeutic MDR circumvention strategies. 
In addition, we have shown that EVs released by MDR cells are capable of stimulating a metabolic alteration 
(towards a MDR phenotype) in recipient drug-sensitive cancer cells.
We confirmed that comparative proteomic approach is a powerful tool to investigate MDR mechanisms in 
cancer cells. MDR and their corresponding drug-sensitive cell lines from two distinct models (chronic myeloid 
leukemia and non-small cell lung cancer) were subjected to a label-free LC-MS quantitative proteomics. The 
obtained data allowed a comparison between the proteome from MDR cells and the one obtained from their 
drug-sensitive counterparts. In terms of biological processes, most of the identified DEPs (differentially expressed 
proteins between drug-sensitive and MDR cells) were involved in metabolic processes and the most active path-
ways enriched were those involved in cellular metabolism (GSH, PPP and Glycolysis). Therefore, we showed that 
the two MDR cell models acquired a similar metabolic profile but significantly distinct from the metabolic profile 
observed in their corresponding drug-sensitive cells.
Interestingly, most of the DEPs involved in the PPP (including the rate limiting enzyme, G6PD) were down-
regulated in the MDR cells. PPP is a pivotal biosynthetic pathway branched to glycolysis and one of the main 
antioxidant cellular defense systems25. PPP has a central role as a source of nucleic acid precursors and provides 
reducing power and ribose phosphate to the cell26. Changes in the PPP activity can affect response to anticancer 
drugs, however the specific role of PPP in MDR phenotype is still unclear. Other authors implied that PPP is more 
active in MDR tumors27,28. Moreover, evidence suggested that elevated levels of NADPH and GSH, together with 
an active PPP, play an important role in MDR29,30. Our results together with other recent studies31,32 contradict 
the above-mentioned reports, showing that PPP enzymes are downregulated in MDR cells. These results are 
controversial since one of the roles of PPP is to provide reducing power to the GSH metabolism and high levels 
of GSH in tumors have been linked to the development of MDR33. In addition, we found increased GSH levels in 
both MDR models, as previously published by other authors34,35. Moreover, since GSH is a detoxification agent36, 
the levels of ROS in the MDR cells were decreased. In all, our results suggest that MDR cells are capable of main-
taining high GSH levels even when PPP is downregulated. Therefore, we assumed that MDR cells upregulated 
another source of GSH.
The methionine cycle is a key pathway for many methylation reactions (methylation of DNA, histones and 
non-histone proteins, such as transcription factors) and could be the source of cysteine residues necessary for 
GSH synthesis37. Growing evidence links aberrant regulation of methylation to tumorigenesis38. The epigenetic 
mechanisms underlying drug resistance have not been fully elucidated, although some studies have suggested 
the contribution of an altered chromatin state to drug resistance39. Our results showed considerable differences 
between MDR and their drug-sensitive cells, in the amount of several metabolites of the methionine/SAMe 
Metabolite description Fold changea ANOVA (P)
K562 vs. K562Dox
Methionine 1.54 2,25E-05
5′ -deoxy-5′ -methylthioadenosine (MTA) 1.44 8,37E-04
S-adenosylhomocysteine (SAH) 0.57 7,67E-06
S-adenosylmethionine (SAMe) 0.99 8,49E-01
Spermidine 0.85 3,68E-03
Betaine 1.02 4,79E-01
Choline 0.63 3,48E-06
Decarboxylated S-adenosyl methionine (dc-
SAMe) 1.42 4,72E-05
Serine 0.50 0
Threonine 0.99 8,59E-01
NCI-H460 vs. NCI-H460/R
Methionine 1.91 3,55E-05
5′ -deoxy-5′ -methylthioadenosine (MTA) 1.13 1,44E-01
S-adenosylhomocysteine (SAH) 0.25 2,42E-05
S-adenosylmethionine (SAMe) 0.99 7,85E-01
Spermidine 0.81 1,33E-02
Betaine 1.71 2,78E-04
Choline 5.94 2,54E-07
Decarboxylated S-adenosyl methionine (dc-
SAMe) 0.50 1,79E-04
Serine 1.04 1,78E-01
Threonine 0.99 8,15E-01
Table 3.  Semi-quantitative analysis of metabolites of the methionine/SAMe pathway in two pairs of MDR 
and their drug-sensitive counterpart cell lines. aMDR cells/drug-sensitive cells.
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pathway. Methionine levels were significantly increased in the MDR cells, which could lead to the GSH increase 
observed in those cells. In addition, the methylation capacity of the cells was increased in both MDR mod-
els and this could be attributed to the metabolic alterations in MDR cells during development of their resist-
ant phenotype. In agreement with our results, other authors have described that treatment with a methylation 
inhibitor reversed drug resistance indicating that the development of some cases of drug resistance could be 
methylation-dependent40. Also, MTA, dcSAMe, betaine, choline and serine are altered in MDR cells, although not 
in a similar manner. These differentially altered metabolites indicate that among these two MDR models there are 
also metabolic differences, which enhance the idea of the complex metabolism associated to MDR.
The energy dependence of drug transport in MDR cells suggests that during development of MDR, cells 
undergo alterations in the energy utilization pathways. The main cell energy carrier, ATP, is produced in two 
metabolic pathways: glycolysis and/or oxidative phosphorylation (OXPHOS) of metabolic fuels22. One of the 
fundamental hallmarks of cancer cells is the shift in the balance between these two energy-production pathways, 
in favor to glycolysis, known as the Warburg effect41–43. For this reason, glycolysis inhibition has attracted sig-
nificant interest as a possible way to sensitize cancer cells to chemotherapy. Indeed, several studies in different 
cancer models have demonstrated an efficient suppression of MDR by glycolytic inhibitors8,23,24,44,45. Moreover, 
during the course of this work another study has suggested the possibility of an accelerated process of glycolysis in 
MDR cells to increase their energy supply46. To our knowledge, a comparison between MDR and drug-sensitive 
cells in terms of metabolic energy supply, using different modulators of glycolysis and OXPHOS, has never been 
performed. The results presented herein showed a statistically significant increase in glycolysis and in the gly-
colytic capacity of the MDR cells (NCI-H460/R), together with a decrease in the mitochondrial basal respira-
tion and in the maximal capacity of the cells to perform OXPHOS compared to the drug-sensitive counterparts 
(NCI-H460). Therefore, our findings indicate that MDR cells, when acquiring the resistant phenotype, enhance 
their switch in the cellular energy supply pathways from OXPHOS to glycolysis. This altered metabolic activity 
in MDR cells could be crucial for: (i) supporting uncontrolled proliferation, since glycolysis provides the inter-
mediates necessary for biosynthetic pathways; (ii) allowing the use of the most abundant extracellular nutrient 
(glucose) to produce abundant ATP. Even though the yield of ATP per glucose consumed is low, if the glyco-
lytic flux is high enough, the percentage of cellular ATP produced by glycolysis can exceed the one produced by 
OXPHOS47,48. Therefore, this metabolic phenotype could be beneficial for MDR cells at both levels of bioenerget-
ics and biosynthesis.
Although MDR cells perform less OXPHOS, the application of different OXPHOS modulators (oligomycin, 
FCCP and rotenone) affected more the drug-sensitive than their MDR counterpart cells. The OCR levels in the 
Figure 4. Global metabolic differences between the NCI-H460 and NCI-H460/R counterpart cell lines. 
Cells were metabolically profiled using Seahorse XF-24 Analyser. (A) Representative results of a glycolysis stress 
test, which measures extracellular acidification rate (ECAR) following addition of glucose-free media (blue line 
A), glucose (blue line B), oligomycin (blue line C) and 2-deoxyglucose (blue line D). (B) Representative results 
of a mitochondrial stress test, measuring the oxygen consumption rate (OCR) in glucose-containing media, 
following sequential addition of media (blue line A), oligomycin (blue line B), FCCP (blue line C) and rotenone 
(blue line D). Results are the mean ± SEM from three independent experiments, with four to eight replicates per 
experiment. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 of NCI- H460 vs. NCI-H460/R cells.
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MDR cells have been less affected than the OCR levels in drug-sensitive cells. This suggests that MDR cells are 
more capable of sustaining the acquired metabolic phenotype in order to maintain the higher energy demand. In 
accordance, it was reported that the relationship between drug resistance and glycolysis may partially be due to 
the radical scavenging potential of the glycolytic intermediates, and the link between them and the cellular redox 
status49.
Furthermore, the increase in glycolysis could be responsible for the decrease in the PPP observed in the MDR 
cells. Since some of the glycolysis and PPP intermediates are the same, it is possible that MDR cells are directing 
these intermediates mostly to glycolysis, in order to sustain the energy for the requested biosynthetic pathways. In 
fact, we demonstrated that when the PPP pathway was inhibited (with DCA50), drug-sensitive cells (NCI-H460) 
acquired a metabolic phenotype similar to that observed in MDR cells by increasing glycolysis and decreasing 
OXPHOS. Also, PPP inhibition increased resistance of sensitive cells to doxorubicin, when compared to sensitive 
cells without PPP inhibition. These results support the hypothesis that there is a competition between glycolysis 
and PPP activity in the MDR phenotype and also that modulation of the PPP and glycolytic pathways is capable 
of altering the sensitivity of cells to drugs.
Figure 5. Alterations in NCI-H460 cell metabolism after treatment with a PPP inhibitor. NCI-H460 
cells were treated with 5 mM DCA for 24 h and subsequently metabolically profiled, using the Seahorse 
XF-24 Analyser. Data represent mean ± SEM from three independent experiments, with four replicates per 
experiment. *p ≤ 0.05; **p ≤ 0.01; NCI-H460 vs. NCI-H460+ DCA. ECAR - extracellular acidification rate; OCR 
- oxygen consumption rate.
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Additionally, in multicellular tumor spheroids and in doxorubicin-resistant human breast adenocarcinoma 
cells, the inhibition of glycolysis raised intracellular ROS, downregulated P-gp and reverted the MDR pheno-
type8,23. In agreement with these data, our work showed that treatment of MDR cells (NCI-H460/R) with a P-gp 
inhibitor (verapamil) switched their metabolic phenotype to that characteristic of sensitive cells (decrease in 
glycolysis and an increase in OXPHOS) and also promoted sensitization of the MDR cells to doxorubicin.
Several studies have associated metabolic alterations with the shedding and cargo of EVs in different types 
of cells (such as increase lactate production18, inhibition of glutamine metabolism19 and the presence of several 
enzymes involved in glucose and glutamine metabolism20). The importance of EVs in the transfer of the MDR 
phenotype has been recently described13,14,51. Therefore, the acquisition by MDR cells of a different metabolic 
Figure 6. Alterations in the NCI-H460/R cellular metabolism after treatment with a P-gp inhibitor. NCI-
H460/R cells were treated with 2 μ M verapamil for 15 h and subsequently metabolically profiled using the 
Seahorse XF-24 Analyser for measuring alterations in glycolysis, glycolytic capacity, glycolytic reserve, non-
glycolytic acidification, basal respiration and non-mitochondrial respiration. Data represent three independent 
experiments, with four replicates per experiment. *p ≤ 0.05; **p ≤ 0.01; NCI-H460/R vs. NCI-H460/R+ 
verapamil. ECAR - extracellular acidification rate; OCR - oxygen consumption rate.
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phenotype, could be responsible for the differences in: (i) the type of EVs population released by MDR cells; (ii) 
their cargo and (iii) the capacity to transfer phenotypes to receiving cells. In fact, we have recently shown that 
MDR cells shed a different population of EVs (more microvesicle-like EVs and less exosomes) when compared to 
the EVs shed by the drug-sensitive counterpart cells17,52. Additionally, our results showed that drug-sensitive cells 
(NCI-H460) co-incubated with EVs from MDR cells (NCI-H460/R and K562Dox), acquired a metabolic pheno-
type (increase in glycolysis) similar to the one observed in MDR cells. These results showed that, independently 
of the origin of the MDR cells (leukemia or lung cancer), their EVs are capable of inducing such alterations. 
However, surprisingly, our results showed that the EVs from the sensitive leukemic cell line were also capable of 
inducing alterations in the glycolytic capacity of the recipient drug-sensitive cells. The reason for this is unknown, 
but is possibly due to the exposure of cells to high levels of EVs, therefore not related to MDR. Furthermore, a 
recent study has described that glutamine metabolism was altered in cancer cells following incubation with large 
EVs (microvesicles), an effect that was not observed upon incubation with exosomes20. This further highlights 
the importance of verifying the type of EVs released by donor cells, since different EVs may transfer different 
phenotypes to receiving cells.
Conclusions
In conclusion, P-gp overexpressing MDR cells may employ various protective metabolic strategies to survive 
(schematically represented in Fig. 9). These include (i) alterations in the GSH metabolism, (ii) increasing the 
methylation index influencing epigenetic regulation, (iii) increasing the rates of glycolysis and (iv) changing the 
phenotype of the surrounding drug-sensitive cells, by EVs mediated transfer of new features. Our results indicate 
that the development of MDR is a complex phenomenon that involves several simultaneous metabolic alterations.
We clarified for the first time the complex metabolic network of the various metabolic alterations associated 
with MDR in cancer cells. In addition, that MDR cancer cells are more capable than drug-sensitive cells of sus-
taining its specific metabolic profile. Specifically, we showed for the first time that MDR cancer cells, besides 
increased glycolysis also have increased glycolytic capacity and glycolytic reserve, while their OXPHOS rate is 
decreased. In addition, our work found differences between MDR and drug-sensitive cells in the amount of sev-
eral metabolites of the methionine/SAMe pathway which regulates DNA and protein methylation, as well as 
GSH production. Finally, we demonstrated for the first time the transfer of metabolic information from MDR to 
drug-sensitive cancer cells through a specific population of EVs.
Materials and Methods
Cell culture. The chronic myeloid leukemia cell line K562 was from European Collection of Cell Cultures 
(ECACC) and its P-gp overexpressing counterpart cell line K562Dox was a kind gift of Dr. J.P. Marie (Paris, 
France)53,54. The non-small cell lung cancer cell line NCI-H460 and its drug-resistant P-gp overexpressing coun-
terpart cell line NCI-H460/R were a kind gift from Dr. M. Pešić (Belgrade, Serbia)55,56. All cell lines were gen-
otyped and routinely monitored for mycoplasma contamination by PCR (VenorGeM® Advance Mycoplasma 
Detection Kit, Minerva). All cells were routinely grown in RPMI-1640 (with Ultraglutamine I and 25 mM 
HEPES) medium (Lonza), supplemented with 10% fetal bovine serum (FBS, PAA) at 37 °C in a humidified incu-
bator with 5% CO2 in air. Cell number and viability were analyzed with trypan blue exclusion assay. All experi-
ments were carried out with exponentially growing cells having over 90% viability.
Figure 7. Alterations in the resistance level of NCI-H460 and NCI-H460/R cells after treatment with PPP 
and P-gp inhibitors, respectively. Cells with or without pre-treatment with DCA or verapamil were treated 
with 37.5 nM of doxorubicin and the ratio between cells with and without pre-treatment was calculated. (A) 
NCI-H460 cells were pre-treated with 5 mM DCA for 24 h. (B)- NCI-H460/R cells were pre-treated with 2 μ M 
verapamil for 15 h. Data represent mean ± SEM from three independent experiments. *p ≤ 0.05.
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Figure 8. Alterations observed in NCI-H460 cellular metabolism after treatment with EVs shed by MDR 
cells. NCI-H460 cells were treated with 18 × 108 EVs for 15 h and subsequently metabolically profiled using 
Seahorse XF-24 Analyser. The results of glycolysis stress test are shown as ECAR measurements after addition of 
glucose-free media (blue line A), glucose (blue line B), oligomycin (blue line C) and 2-deoxyglucose (blue line 
D). (A) NCI-H460 cells were treated with their own EVs and with EVs isolated from NCI-H460/R cells.  
(B) NCI-H460 cells were treated with EVs isolated from the pair of chronic myeloid leukaemia counterpart 
cells, K562 and K562Dox. Data represents the results from two independent experiments, with four replicates 
each. A two-tailed *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 NCI-H460 vs. NCI-H460+ EVs NCI-H460; NCI-H460 vs. 
NCI-H460+ EVs NCI-H460/R; NCI.H460 vs. NCI-H460+ EVs K562; NCI-H460 vs. NCI-H460+ EVs K562Dox.
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Sample preparation and mass spectrometry using LC/MS/MS. Pellets from cells (K562, K562Dox, 
NCI-H460 and NCI-H460/R) were processed and 10 μ g of proteins were analyzed by mass spectrometry using 
LC/MS/MS as previously described17. Biological replicates (from 4 independent experiments) were analyzed for 
each sample type.
Label-Free LC-MS quantitative profiling. Label-free LC–MS analysis was carried out using Progenesis 
QI for proteomics v4.1 software (NonLinear Dynamics, UK), essentially as recommended by the manufacturer 
(see www.nonlinear.com for further background to alignment, normalization, calculation of peptide abundance, 
etc.).
This software extracts quantitative information from MS1 data by aligning the data based on the LC retention 
time of each sample to a reference file (sample run that yielded most peptide ions); this allows for any drift in 
retention time, giving an adjusted retention time for all runs in the analysis.
Results were filtered, based on statistical analysis. The Progenesis peptide quantification algorithm calculates 
peptide abundance as the sum of the peak areas within its isotope boundaries. Each abundance value is then 
transformed to a normalized abundance value by applying a global scaling factor. Protein abundance was calcu-
lated as the sum of the abundances of all peptide ions, which have been identified as coming from the same pro-
tein. Any peptides with an ANOVA score of p > 0.05 were eliminated. The MS2 data for the remaining peptides 
was exported and the resulting MGF file used to search the NewUniProtSwissprot database (updated in January 
2014) on the MASCOT server (www.matrixscience.com) for protein identifications. The search parameters used 
were as follows: (1) species, Homo sapiens; (2) allowed number of missed cleavages, 2; (3) fixed modification, 
carboxylmethyl; (4) variable modifications, methionine oxidation; (5) peptide mass tolerance ± 20 ppm; (6) MS/
MS tolerance ± 0.6 Da; and (7) peptide charge + 1, + 2 and + 3. Only peptides with ion scores of 40 and above 
were considered and re-imported back into Progenesis QI software for further analysis. Peptide identifications 
were imported into the Progenesis software and assigned to the matching features. Protein scores were based on 
ANOVA values with a cut off of p < 0.05. Differentially expressed proteins (DEPs) between drug-sensitive and 
MDR cells with ≥ 2 peptides matched and a ≥ 1.5 fold differences in abundance were considered as significant. 
Peptide conflicts occur when a peptide is identified as present in more than one protein. These were resolved by 
assigning the peptide to the protein with the greater number of hits, a greater Mascot score or a lower mass error; 
when conflicts could not be clearly resolved, the peptide was excluded from the analysis.
Bioinformatics analysis of the detected DEPs. The two data sets (DEPs from K562 vs. K562Dox cells 
and NCI-H460 vs. NCI-H460/R cells) were analyzed using bioinformatics methods. Database for Annotation, 
Visualization, and Integrated Discovery (DAVID 6.7) was used to identify protein and molecular pathway modifi-
cations. UniProt accession numbers were obtained by Progenesis software. To understand the high-level functions 
and utilization of the biological systems from molecular-level information, the Kyoto Encyclopedia of Genes and 
Figure 9. Schematic representation of the observed metabolic differences between drug-sensitive cells 
and their counterpart MDR cells. P-gp overexpressing MDR cancer cells have various protective metabolic 
strategies. These include: increasing rates of glycolysis (1) and methylation capacity (2), alterations in the 
GSH metabolism (3), decreasing rates of PPP (4) and OXPHOS (5) and finally changing the phenotype of the 
surrounding drug-sensitive cells by EVs-mediated transfer of new features (6). Filled lines and arrows: increased 
pathways; Dashed lines and arrows: decreased pathways; Bold and bigger fonts: increased metabolic processes; 
Smaller fonts: decreased metabolic processes.
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Genomes (KEGG) pathway was used. Distributions in subcellular locations, biological processes and molecular 
functions were assigned to each protein based on Gene Ontology (GO) categories. The significantly (p < 0.05) 
enriched categories are presented.
Analysis of Protein Expression by Western Blot. Cell pellets were lysed in Winman’s Buffer (1% NP-40, 
0.1 M Tris-HCl pH 8.0, 0.15 M NaCl and 5 mM EDTA) with EDTA-free protease inhibitor cocktail (Roche). Total 
protein content of cell lysates was quantified with “DC Protein assay kit” (Bio-Rad) and 20 μ g of protein were 
subjected to SDS-PAGE (12% Bis-Tris gel). Following electrophoretic transfer of the proteins into nitrocellulose 
membranes (GE Healthcare, UK), membranes were then incubated with the following primary antibodies: goat 
anti-Actin (1:2000; Santa Cruz Biotechnology), mouse anti-P-gp (P7965) (1:2000; Sigma), G6PD (1:200; Santa 
Cruz Biotechnology), 6PGD (1:200; Santa Cruz Biotechnology) and IDH1 (1:200; Santa Cruz Biotechnology). 
The following secondary antibodies were then used: anti-mouse IgG-HRP; anti-rabbit IgG-HRP or anti-goat 
IgG-HRP (all diluted 1:2000; Santa Cruz Biotechnology). Signal was detected using the ECL Western blot 
Detection Reagents (GE Healthcare, UK), the Amersham Hyperfilm ECL (GE Healthcare, UK), and the Kodak 
GBX developer and fixer (Sigma, EUA)57. The intensity of the bands obtained in each film was further analyzed 
using the software Quantity One – 1D Analysis (Bio-Rad, USA).
GSH/GSSG-GloTM assay. To measure GSH levels, the GSH/GSSG-GloTM Assay (Promega, USA) was 
used following manufacturer’s instructions. Briefly, 5000 cells/well were plated in white 96-opaque well plates. 
NCI-H460 and NCI-H460/R cells were plated in 100 μ l of RPMI-1640; K562 and K562Dox cells were plated 
in 20 μ l of Hanks Balanced Salt Solution (HBSS). Total glutathione lysis reagent or oxidized glutathione lysis 
reagent were added to the cells. After incubation at room temperature a luciferin generation reagent was added 
to all samples and the plates were incubated for 30 min at room temperature. Luminescence was quantified 
using a microplate reader (Biotek Instruments Inc. Synergy MX. USA). Positive control (cells treated with 5 μ M 
staurosporine for 4 h) and wells with no cells were also included as controls. GSH levels were calculated as follows: 
GSH levels = total glutathione levels – oxidized glutathione levels.
ROS Detection. 2′ ,7′ -dichlorodihydrofluorescein diacetate (H2DCF-DA) analysis by flow cytometry were 
used to measure ROS concentration in drug-sensitive and MDR cells. K562 and K562Dox cells (8 × 105/well) 
were plated in 6-well plates; NCI-H460 and NCI-H460/R cells (3 × 105/well) were plated in 6-well plates for 24 h. 
Cells were harvested and incubated in adequate medium with 10 μ M CM-H2DCFDA for 45 min at 37 °C in the 
dark. Cells were subsequently washed twice in PBS and the CM-H2DCFDA fluorescence was analyzed in a BD 
Accuri flow cytometer (FL1-H channel). A positive control (cells treated with 1 μ M staurosporine for 6 h) was also 
included. Mean fluorescence intensity was calculated after correction for auto-fluorescence.
Semi-quantitative analysis of metabolites of the methionine/S-adenosylmethionine path-
way. Total cell pellets (4 independent preparations for each cell line) were lysed in 500 μ L of a mixture of 
ice-cold water/metanol/10 mM acetic acid (49/50/1 v/v/v%) with a tissue homogenizer (Precellys) in 1 × 20 sec-
ond cycles at 6000 rpm. Subsequently, 400 μ L of the homogenate was transferred to a new aliquot and shaken at 
1400 rpm for 30 minutes at 4 °C. Next the aliquots were centrifuged for 15 min at 14000 rpm at 4 °C. 75 μ L of the 
supernatant was transferred to a fresh aliquot and placed at − 80 °C for 20′ . The chilled supernatants were evap-
orated with a speedvac in approximately 3 h. The resulting pellets were resuspended in 100 μ L water/acetonitrile 
(MeCN)/formic acid (40/60/0.1 v/v/v%, resuspension solution).
Concentrations of methionine, MTA, SAMe, SAH, spermidine and spermine were determined with a 
semi-quantitative method. Calibration curves for these compounds were obtained, by measuring serial dilutions 
of a pooled standard mixture in resuspension solution. The concentrations for all compounds in the dilutions 
ranged from 100 μ M to 0.025 μ M. For the standard mixtures, separate 10 mM stocks of the standards were made. 
These were then pooled and further diluted in resuspension solution in order to obtain the final concentrations 
as used for the calibration curve.
Samples were measured with a UPLC system (Acquity, Waters, Manchester) coupled to a Time of Flight mass 
spectrometer (ToF MS, SYNAPT G2, Waters). A 2.1 × 100 mm, 1.7 μ m BEH amide column (Waters), thermo-
stated at 40 °C, was used to separate the analytes before entering the MS. Solvent A (aqueous phase) consisted of 
99.5% water, 0.5% formic acid and 20 mM ammonium formate while solvent B (organic phase) consisted of 29.5% 
water, 70% MeCN, 0.5% formic acid and 1 mM ammonium formate.
In order to obtain a good separation of the analytes the following gradient was used: from 5% A to 50% A 
in 2.4 minutes in curved gradient (#8, as defined by Waters), from 50% A to 99.9% A in 0.2 minutes constant at 
99.9% A for 1.2 minutes, back to 5% A in 0.2 minutes. The flow rate was 0.250 mL/min and the injection volume 
was 2 μ L. All samples were injected randomly. After every 10 injections a QC sample was injected. All samples 
were injected in duplicate.
Analytes were measured in enhanced duty cycle (EDC) mode, optimized for the mass of the analyte in ques-
tion. MTA was measured in scan function 1 (EDC at 298), choline was measured in scan function 2 (EDC at 104), 
methionine was measured in scan function 3 (EDC at 150), SAH was measured in scan function 8 (EDC at 385), 
SAMe was measured in scan function 10 (EDC at 399), spermidine was measured in scan function 12 (EDC at 
146), spermine was measured in scan function 13 (EDC at 203). The cone voltage was between 20 and 25 depend-
ing on the analyte. A 2 ng/mL leucine-enkephalin solution in water/acetonitrile/formic acid (49.9/50/0.1%v/v/v) 
was infused at 10 μ L/min and used for a lock mass which was measured each 47 seconds for 0.5 seconds. Spectral 
peaks were automatically corrected for deviations in the lock mass.
Extracted ion traces were obtained for methionine (m/z = 150.0589), SAH (m/z = 385.1294), SAMe 
(m/z = 399.1451), MTA (m/z = 298.097), spermidine (m/z = 146.1657) and Spermine (m/z = 203.2236) in a 
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20 mDa window and subsequently smoothed (2 points, 2 iterations) and integrated with QuanLynx software 
(Waters, Manchester).
Extracellular flux assay using Seahorse XF-24 Analyser. ECAR, reflecting the rate of glycolysis, and 
OCR, reflecting the rate of OXPHOS, were measured using a Seahorse Bioscience (Copenhagen, Denmark) XF24 
analyzer. Briefly, 2 × 104 cells/well for glycolysis stress test and 3 × 104 cells/well for mitochondrial stress test were 
plated in Seahorse XF24 plates in 200 μ l of RPMI-1640 and incubated for 20–24 h at 37 °C in a humidified incuba-
tor with 5% CO2 in air and 1 h hour prior to the XF assay in a humidified incubator without CO2 with the corre-
sponding assay media. In the experiments where the cells were treated with DCA, the treatment was performed 
for 24 h with a concentration of 5 mM. The verapamil treatment was performed for 15 h with 2 μ M. NCI-H460/R 
treated with DCA and NCI-H460 treated with verapamil were used as controls.
Basal OCR measurements were made in DMEM containing 10 mM sodium pyruvate (Invitrogen, California, 
EUA), 10 mM Glucose (Invitrogen, California, EUA) and 10 mM Glutamax (Invitrogen, California, EUA) and 
Basal ECAR measurements were made in DMEM without any supplementation.
Steady-state (baseline) oxygen consumption rates and extracellular acidification rates were measured. 
Non-glycolytic acidification, glycolysis, glycolytic capacity and glycolytic reserve were measured, through ECAR, 
by injecting: glucose, oligomycin and 2-deoxyglucose. Basal respiration, proton leak, spare capacity, maximal res-
piration, non-mitochondrial respiration and ATP production were measured, through OCR, after the sequential 
injection of oligomycin, FCCP and rotenone. All measurements were normalized to protein quantity with crystal 
violet.
Sulforhodamine B assay. The Sulforhodamine B (SRB) assay was performed to measure cell growth indi-
rectly, by measuring total protein content. The NCI-H460 and NCI-H460/R cells were seeded in 96-well plates 
(5000 cells/well), and pre-treated with 5 mM DCA for 24 h or with 2 μ M verapamil for 15 h, respectively. Cells 
were then treated in duplicate with 3 serial dilutions of doxorubicin (37.5 nM, 75 nM and 150 nM) for 48 h. Cells 
were fixed with 10% (w/v) ice cold trichloroacetic acid (TCA) and then washed with distilled water. After staining 
proteins with 0.4% (w/v) SRB, cells were washed with 1% (v/v) acetic acid, the bound SRB was solubilized with 
10 mM Tris base and absorbance was measured at 510 nm in a multiplate reader (Synergy Mx, Biotek Instruments 
Inc.). The ratio between cells with a pre-treatment and cells without the pre-treatment was calculated. NCI-H460 
treated with DCA only and NCI-H460/R treated with verapamil only were used as controls.
Co-culture of H460 cells with EVs. EVs were isolated from the culture media of drug-sensitive or MDR 
cells by various centrifugation steps as previously described17. EVs pellets were re-suspended in 100 μ l of PBS and 
frozen at − 80 °C. NCI-H460 cells were treated with 18 × 108 EVs (quantified by nanoparticle tracking analysis as 
in Supplementary Information) for 15 hours and were subsequently metabolically profiled using Seahorse XF-24 
Analyzer.
Statistical analysis. All presented data resulted from at least three independent experiments (excluding the 
EVs treatment which was performed in two independent experiments only). All data was statistically analyzed 
with the two-tailed unpaired Student’s t-test. Results were considered statistically significant when p ≤ 0.05.
References
1. Larsen, A. K., Escargueil, A. E. & Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of 
anticancer agents. Pharmacol Ther 85, 217–229 (2000).
2. Lopes-Rodrigues, V. et al. The network of P-glycoprotein and microRNAs interactions. International journal of cancer. Journal 
international du cancer 135, 253–263, doi: 10.1002/ijc.28500 (2014).
3. Eckford, P. D. & Sharom, F. J. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109, 2989–3011, doi: 10.1021/
cr9000226 (2009).
4. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews. Cancer 
2, 48–58, doi: 10.1038/nrc706 (2002).
5. Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123, 3664–3671, 
doi: 10.1172/JCI67230 (2013).
6. Koczula, K. M. et al. Metabolic plasticity in CLL: adaptation to the hypoxic niche. Leukemia: official journal of the Leukemia Society 
of America, Leukemia Research Fund, UK 30, 65–73, doi: 10.1038/leu.2015.187 (2016).
7. Zub, K. A. et al. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in 
multiple myeloma cells. PloS One 10, e0119857, doi: 10.1371/journal.pone.0119857 (2015).
8. Wartenberg, M. et al. Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of 
the intracellular redox state. J Cell Biochem 109, 434–446, doi: 10.1002/jcb.22422 (2010).
9. Milane, L., Duan, Z. & Amiji, M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells 
and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell 
Int 11, 3, doi: 10.1186/1475-2867-11-3 (2011).
10. D'Souza-Schorey, C. & Clancy, J. W. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and 
prospective cancer biomarkers. Genes & development 26, 1287–1299, doi: 10.1101/gad.192351.112 (2012).
11. Kucharzewska, P. & Belting, M. Emerging roles of extracellular vesicles in the adaptive response of tumour cells to 
microenvironmental stress. J Extracell Vesicles 2, doi: 10.3402/jev.v2i0.20304 (2013).
12. Yanez-Mo, M. et al. Biological properties of extracellular vesicles and their physiological functions. Journal of extracellular vesicles 4, 
27066, doi: 10.3402/jev.v4.27066 (2015).
13. Bebawy, M. et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia: official 
journal of the Leukemia Society of America, Leukemia Research Fund, UK 23, 1643–1649, doi: 10.1038/leu.2009.76 (2009).
14. Corcoran, C. et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance 
transfer via exosomes. PloS One 7, e50999, doi: 10.1371/journal.pone.0050999 (2012).
15. Pasquier, J. et al. Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 
breast cancer cells. The Journal of biological chemistry 287, 7374–7387, doi: 10.1074/jbc.M111.312157 (2012).
www.nature.com/scientificreports/
1 6Scientific RepoRts | 7:44541 | DOI: 10.1038/srep44541
16. Zhang, F. F. et al. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, 
conferring paclitaxel-resistance. Eur J Pharmacol 738, 83–90, doi: 10.1016/j.ejphar.2014.05.026 (2014).
17. Lopes-Rodrigues, V. et al. Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-
sensitive counterpart cells. Biochimica et biophysica acta 1860, 618–627, doi: 10.1016/j.bbagen.2015.12.011 (2016).
18. Fruhbeis, C., Helmig, S., Tug, S., Simon, P. & Kramer-Albers, E. M. Physical exercise induces rapid release of small extracellular 
vesicles into the circulation. J Extracell Vesicles 4, 28239, doi: 10.3402/jev.v4.28239 (2015).
19. Santana, S. M., Antonyak, M. A., Cerione, R. A. & Kirby, B. J. Cancerous epithelial cell lines shed extracellular vesicles with a 
bimodal size distribution that is sensitive to glutamine inhibition. Phys Biol 11, 065001, doi: 10.1088/1478-3975/11/6/065001 (2014).
20. Minciacchi, V. R. et al. Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived 
extracellular vesicles. Oncotarget 6, 11327–11341, doi: 10.18632/oncotarget.3598 (2015).
21. van Liempd, S., Cabrera, D., Mato, J. M. & Falcon-Perez, J. M. A fast method for the quantitation of key metabolites of the 
methionine pathway in liver tissue by high-resolution mass spectrometry and hydrophilic interaction ultra-performance liquid 
chromatography. Anal Bioanal Chem 405, 5301–5310, doi: 10.1007/s00216-013-6883-4 (2013).
22. Rahman, M. & Hasan, M. R. Cancer Metabolism and Drug Resistance. Metabolites 5, 571–600, doi: 10.3390/metabo5040571 (2015).
23. Ma, S., Jia, R., Li, D. & Shen, B. Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast 
Adenocarcinoma Cells. Biomed Res Int 2015, 453986, doi: 10.1155/2015/453986 (2015).
24. Xu, R. H. et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial 
respiratory defect and hypoxia. Cancer research 65, 613–621 (2005).
25. Kruger, N. J. & von Schaewen, A. The oxidative pentose phosphate pathway: structure and organisation. Curr Opin Plant Biol 6, 
236–246 (2003).
26. Eggleston, L. V. & Krebs, H. A. Regulation of the pentose phosphate cycle. Biochem J 138, 425–435 (1974).
27. Polimeni, M. et al. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J 439, 
141–149, doi: 10.1042/BJ20102016 (2011).
28. Chen, Y. et al. Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway. Sci Rep 5, 9925, 
doi: 10.1038/srep09925 (2015).
29. Estrela, J. M., Ortega, A. & Obrador, E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43, 143–181, doi: 
10.1080/10408360500523878 (2006).
30. Meijerman, I., Beijnen, J. H. & Schellens, J. H. Combined action and regulation of phase II enzymes and multidrug resistance 
proteins in multidrug resistance in cancer. Cancer treatment reviews 34, 505–520, doi: 10.1016/j.ctrv.2008.03.002 (2008).
31. Wang, Z. et al. Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis. Sci 
Rep 5, 9301, doi: 10.1038/srep09301 (2015).
32. Gehrmann, M. L., Fenselau, C. & Hathout, Y. Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. J 
Proteome Res 3, 403–409 (2004).
33. Townsend, D. M. & Tew, K. D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369–7375, doi: 
10.1038/sj.onc.1206940 (2003).
34. Krzyzanowski, D., Bartosz, G. & Grzelak, A. Collateral sensitivity: ABCG2-overexpressing cells are more vulnerable to oxidative 
stress. Free radical biology & medicine 76, 47–52, doi: 10.1016/j.freeradbiomed.2014.07.020 (2014).
35. Tai, D. J. et al. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp Ther Med 4, 
291–296, doi: 10.3892/etm.2012.591 (2012).
36. Dirven, H. A., van Ommen, B. & van Bladeren, P. J. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard 
group and the role of glutathione S-transferases. Chem Res Toxicol 9, 351–360, doi: 10.1021/tx950066l (1996).
37. Wang, S. T., Chen, H. W., Sheen, L. Y. & Lii, C. K. Methionine and cysteine affect glutathione level, glutathione-related enzyme 
activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr 127, 2135–2141 (1997).
38. Montenegro, M. F. et al. Targeting the epigenetic machinery of cancer cells. Oncogene 34, 135–143, doi: 10.1038/onc.2013.605 (2015).
39. Chen, C. C. et al. Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells. 
Cancer Cell Int 15, 98, doi: 10.1186/s12935-015-0248-3 (2015).
40. Onda, K. et al. Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases 
drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines. Anticancer Res 32, 4439–4444 (2012).
41. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674, doi: 10.1016/j.cell.2011.02.013 (2011).
42. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nature reviews. Cancer 11, 85–95, doi: 10.1038/
nrc2981 (2011).
43. Warburg, O. On respiratory impairment in cancer cells. Science 124, 269–270 (1956).
44. Koshkin, V., Ailles, L. E., Liu, G. & Krylov, S. N. Metabolic Suppression of a Drug-Resistant Subpopulation in Cancer Spheroid Cells. 
J Cell Biochem 117, 59–65, doi: 10.1002/jcb.25247 (2016).
45. Tavares-Valente, D., Baltazar, F., Moreira, R. & Queiros, O. Cancer cell bioenergetics and pH regulation influence breast cancer cell 
resistance to paclitaxel and doxorubicin. Journal of bioenergetics and biomembranes 45, 467–475, doi: 10.1007/s10863-013-9519-7 (2013).
46. Qinghong, S. et al. Comparative proteomics analysis of differential proteins in respond to doxorubicin resistance in myelogenous 
leukemia cell lines. Proteome Sci 13, 1, doi: 10.1186/s12953-014-0057-y (2015).
47. Guppy, M., Greiner, E. & Brand, K. The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and 
proliferating thymocytes. Eur J Biochem 212, 95–99 (1993).
48. Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
49. Sattler, U. G., Walenta, S. & Mueller-Klieser, W. [Lactate and redox status in malignant tumors]. Anaesthesist 56, 466–469, 
doi: 10.1007/s00101-007-1164-2 (2007).
50. De Preter, G. et al. Inhibition of the pentose phosphate pathway by dichloroacetate unravels a missing link between aerobic glycolysis 
and cancer cell proliferation. Oncotarget 7, 2910–2920, doi: 10.18632/oncotarget.6272 (2016).
51. Sousa, D., Lima, R. T. & Vasconcelos, M. H. Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles. Trends 
in molecular medicine 21, 595–608, doi: 10.1016/j.molmed.2015.08.002 (2015).
52. Lopes-Rodrigues, V. et al. Data supporting the shedding of larger extracellular vesicles by multidrug resistant tumour cells. Data 
Brief 6, 1023–1027, doi: 10.1016/j.dib.2016.02.004 (2016).
53. Marie, J. P., Faussat-Suberville, A. M., Zhou, D. & Zittoun, R. Daunorubicin uptake by leukemic cells: correlations with treatment 
outcome and mdr1 expression. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 7, 
825–831 (1993).
54. Seca, H., Lima, R. T., Guimaraes, J. E. & Helena Vasconcelos, M. Simultaneous targeting of P-gp and XIAP with siRNAs increases 
sensitivity of P-gp overexpressing CML cells to imatinib. Hematology 16, 100–108, doi: 10.1179/102453311X12940641877803 
(2011).
55. Pesic, M. et al. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J 
Chemother 18, 66–73, doi: 10.1179/joc.2006.18.1.66 (2006).
56. Podolski-Renic, A. et al. Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new 
compounds testing. Cancer Chemother Pharmacol 72, 683–697, doi: 10.1007/s00280-013-2247-1 (2013).
57. Lima, R. T., Martins, L. M., Guimaraes, J. E., Sambade, C. & Vasconcelos, M. H. Chemosensitization effects of XIAP downregulation 
in K562 leukemia cells. Journal of chemotherapy 18, 98–102, doi: 10.1179/joc.2006.18.1.98 (2006).
www.nature.com/scientificreports/
17Scientific RepoRts | 7:44541 | DOI: 10.1038/srep44541
Acknowledgements
This article is a result of the project NORTE-01-0145-FEDER-000029, supported by Norte Portugal Regional 
Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European 
Regional Development Fund (ERDF). This work was partially financed by FEDER - Fundo Europeu de 
Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness 
and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT - Fundação para a 
Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project "Institute 
for Research and Innovation in Health Sciences" (POCI-01-0145-FEDER-007274). Health Basque Government 
(2015111149 to JM-F), Ramón Areces Foundation to JM-F, Instituto de Salud Carlos III (PI12/01604 to JM-F), 
Spanish Ministry of Economy and Competitiveness MINECO (SAF2015-66312 to JM-F) all of them co-financed 
by ERDF (FEDER) Funds from the European Commission, “A way of making Europe”. The authors thank the 
Portuguese Foundation for Science and Technology (FCT) for the PhD grant of VLR (SFRH/BD/87646/2012) 
and for the post-doc grant of RTL (SFRH/BPD/68787/2010). The authors also acknowledge the European COST 
Action for supporting the European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD, 
BM1202) and funding the short-term mission (ECOST-STSM-BM1202-180216-071544) of VR to CIC bioGUNE.
Author Contributions
V.L.R. carried out most of the laboratory work and wrote the manuscript. J.M., D.C. and S.V.L. helped in the 
metabolism-related experiments and analysis of data. A.D.L., P.M. and M.H. provided expertise in proteomic 
analysis and helped with the bioinformatics analysis of data. M.P. provided the lung cancer pair of cell lines, had 
several critical discussions with M.H.V. and proof-read the manuscript. R.T.L., R.O.C. and J.M.F.P. co-supervised 
some of the experiments, helped planning those experiments and proof-read the manuscript. R.O.C. and J.M.F.P. 
were responsible for supervising the work that was carried out in Dublin and Bilbao, respectively, and provided 
necessary reagents and facilities. M.H.V. was the main supervisor of this work and was responsible for most of 
the funding, conceiving the study, planning and coordinating the work and helping writing the manuscript. All 
authors agreed with the last version of the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing Interests: The authors declare no competing financial interests.
How to cite this article: Lopes-Rodrigues, V. et al. Identification of the metabolic alterations associated with the 
multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles. Sci. 
Rep. 7, 44541; doi: 10.1038/srep44541 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2017
